Despite significant progress in clinical management, drug resistance remains a major
obstacle. Recent research based on protein degradation to restrain drug resistance has …

Highlights•Drug resistance towards chemotherapy and molecularly targeted therapies
remains a great challenge in cancer treatments.•Deubiquitinating enzymes (DUBs) regulate …

Background Exosomes play crucial roles in regulating the crosstalk between normal and
cancer cells in the tumor microenvironment, and in regulating cancer proliferation, migration …

Exploiting cancer metabolism for the clinical benefit of patients with hepatocellular
carcinoma (HCC) is a topic under active investigation. Ubiquitin-specific peptidase 48 …

Objective We aimed to elucidate the mutual regulation mechanism of ubiquitin-specific
protease 22 (USP22) and hypoxia inducible factor-1α (HIF1α), and the mechanism they …

Background Multi-drug resistance is the major cause of chemotherapy failure in
hepatocellular carcinoma (HCC). YAP, a critical effector of the Hippo pathway, has been …

Overexpression of the deubiquitylase ubiquitin-specific peptidase 22 (USP22) is a marker of
aggressive cancer phenotypes like metastasis, therapy resistance, and poor survival …

Sorafenib is a multi-kinase inhibitor and one of the few systemic treatment options for
patients with advanced hepatocellular carcinomas (HCCs). Resistance to sorafenib …

Deubiquitylating enzymes (DUBs) maintain relative homeostasis of the cellular ubiquitome
by removing the post‐translational modification ubiquitin moiety from substrates. Numerous …

Background Chemotherapy has been widely used to treat cancer, but the appearance of
multidrug resistance (MDR) is the biggest obstacle to successful chemotherapy. One of the …